Boehringer Asks DC Circ. To Rethink Doc Ruling In FTC Probe
Boehringer Ingelheim Pharmaceuticals Inc. asked the D.C. Circuit on Monday for another shot at defending a lower court order that largely rejected the Federal Trade Commission's documents request in its investigation...To view the full article, register now.
Already a subscriber? Click here to view full article